AmpliPhi Announces the Appointment of Baxter Phillips
News Nov 14, 2013
AmpliPhi BioSciences Corporation. has announced that it has appointed Baxter Phillips, III, to the newly created position of Vice President, Corporate Strategy and Business Development.
Mr. Phillips has more than 15 years of experience in leading multinational corporate strategy efforts and structuring, negotiating, and executing strategic alliances, licenses and collaborations in the biotechnology and pharmaceutical industry.
Mr. Phillips will lead a variety of corporate and business development initiatives at AmpliPhi. Mr. Phillips will be U.S. based and reports directly to Philip J. Young, President and Chief Executive Officer of AmpliPhi.
“Baxter’s diverse background and successful global experiences in strategy, finance and licensing, will help accelerate AmpliPhi’s corporate initiatives as we continue our progress and growth to become the leading bacteriophage Company developing and delivering novel antibiotic therapies” said Mr. Young.
Before joining AmpliPhi, Mr. Phillips was Director of Business Development at Depomed, Inc. where he led efforts to enter new collaborations with the company’s platform formulation technology.
Additionally, Mr. Phillips was responsible for licensing the company’s product portfolio of both development-stage and marketed products on a global basis, including the U.S, Europe, Japan and Latin America.
Prior to Depomed, Mr. Phillips served as Senior Director, Corporate Development at Osteologix, where he worked directly with Mr. Young for four years as the team developed a novel therapy for osteoporosis, which resulted in a successful global licensing deal with a multinational pharmaceutical company.
Prior to Osteologix, Mr. Phillips was with Insmed, Inc. for ten years where he held a range of leadership positions in research, licensing, finance, investor relations, and sales and marketing.
Mr. Phillips received his MBA from the College of William and Mary and his Bachelor of Science in Biology from Hampden-Sydney College.
Commenting on his appointment Mr. Phillips said: “I am extremely pleased to join Phil and the great team at AmpliPhi in an effort to continue on our mission to be a leader in developing novel antibacterial treatments. As we embark on the age of the post-antibiotic era with ever increasing drug resistance, our mission to find new treatments is critically important to our global stakeholder community, including the millions of individuals not receiving effective antibiotic treatments.”
Absolute Antibody and Kerafast Merge Increasing Access to Unique Reagents and Recombinant Antibody TechnologyNews
Absolute Antibody Ltd., and Kerafast Inc., have announced a merger of the two companies. The merger brings together two companies with a shared commitment to improving the selection of research tools available to the scientific community.READ MORE
Lonza to Establish Cell- and Gene-Therapy Centers of Excellence to Accelerate GrowthNews
Lonza will establish Centers of Excellence for Cell and Gene Therapy to support and accelerate the growth of this priority area for the company.READ MORE